Rubicon Research IPO GMP

October 14, 2025 Written By Mihir Gohel, Reviewed and Fact Checked by Harpal Parmar

Rubicon Research IPO is a significant offering opening on October 9, 2025, and closing on October 13, 2025, with a price band of ₹461 to ₹485 per equity share. The IPO aims to raise ₹1,377.5 crore, including a fresh issue of ₹500 crore and an offer for sale of ₹877.5 crore by promoters. With a solid product portfolio and growth prospects driven by innovation and regulatory approvals, Rubicon Research IPO offers investors entry into a growing pharma segment.

₹130

Latest IPO GMP

Last updated on 14 Oct 2025 11.51

₹485

IPO Offer Price

*cut off price

₹

Listing Price

Listing Date 16/10/2025

Expert Opinions

Market sentiment for Rubicon Research IPO is optimistic, supported by the company’s rapid revenue growth and expanding product approvals in the US pharmaceutical market. The company’s strengths include a robust portfolio of specialty and generic formulations, strong R&D capabilities in India and Canada, and regulatory compliance with US FDA, WHO-GMP, and Health Canada standards. Rubicon has a competitive edge with 72 active ANDAs and 9 NDAs approved, positioning it as a significant player in regulated markets.

Risks encompass dependence on the US market, regulatory challenges, and volatility in R&D outcomes. The valuation analysis for financial year 2025 highlights Rubicon Research IPO with a Return on Equity (ROE) of 29.02%, Return on Capital Employed (ROCE) of 26.45%, and Net Asset Value (NAV) of ₹35.53, underscoring profitability and capital efficiency. Long-term investors may find potential in Rubicon’s strong market foothold and innovation pipeline.

Investor Considerations

Rubicon Research IPO demonstrates solid company performance with revenues rising 49% from ₹872.39 crore in FY 2024 to ₹1,296.22 crore in FY 2025 and a PAT margin of 10.37%, indicating healthy profitability. The pharmaceutical formulations sector outlook remains robust, driven by increasing demand in regulated markets, especially the US. The Rubicon Research IPO valuation for financial year 2025 shows a Return on Net Worth of 29.02%, EBITDA Margin of 20.67%, and Debt to Equity ratio of 0.51, reflecting strong financial health and moderate leverage.

Growth prospects are fueled by a rich pipeline of ANDAs and NDAs, regulatory approvals, and expanding US market presence. Risks include regulatory compliance, dependency on US markets, and R&D uncertainties. Long-term investors may benefit from Rubicon’s innovation-driven growth, while short-term investors should watch market/listing conditions closely.